Navigation Links
Regulatory Affairs Associates Gets New Drugs Tested Faster, Wins 2007 Innovation Michigan Award
Date:10/17/2007

Micro-Plants Introduced to Accelerate Manufacture of Clinical Trial

Pharmaceuticals

FARMINGTON HILLS, Mich., Oct. 17 /PRNewswire/ -- Regulatory Affairs Associates (RAA), a Michigan company specializing in winning FDA approval for new drugs and medical devices, has been honored as a recipient of the 2007 Innovation Michigan award. RAA received the award for its development of a fast-track process for the manufacture of drugs used in clinical trials called "NDX."

(Photo: http://www.newscom.com/cgi-bin/prnh/20071017/CLW136 )

Production of experimental drugs for use in clinical trials is an expensive, critical step for biotechnology companies working on new drugs. RAA's "New Drug Xpeditor" (NDX) program uses a micro-plant model to slash both the time and money required for this effort. Says Norm Howe, RAA's Director of Manufacturing Services, "What we have done is turn an arduous serial process into a highly efficient collection of simultaneous, parallel processes. The results are experimental drugs produced to FDA quality standards in a fraction of the time and money. NDX has the ability to accelerate most drug development projects and save many more that could be shelved for lack of funds."

Regulatory Affairs Associates, which delivers its NDX micro-plant program under its RAA Pharma Manufacturing Services unit, was one of 15 honorees on October 4th at Michigan Business Review's Innovation Michigan 2007 celebration in Dearborn, Michigan. RAA was lauded in the category of "Innovative Processes" for its ground-breaking methodology.

"NDX is one new way RAA can help emerging biotech companies successfully develop promising new drugs that may save lives or reduce suffering," says Steve Goldner, RAA's president and founder. "It's gratifying work and we're proud to have achieved this recognition."

Sponsored by Michigan Business Review magazine, the Innovative Michigan awards honor Michigan companies whose products, processes or business strategies are distinguished from their peers.

Regulatory Affairs Associates (http://www.regaffairs.net) is a privately held Michigan company that helps biotechnology firms bring new drugs and medical devices to market. The company is a highly regarded expert at navigating the complex FDA approval process. RAA's Pharma Manufacturing and Research Services units provide its U.S. and foreign-based clients with experimental drug production, pre-clinical toxicology studies and contract clinical research services. RAA's innovative business model brings highly experienced drug and device development professionals from around the world into collaboration using the latest communications and Internet technologies.


'/>"/>
SOURCE Regulatory Affairs Associates, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Handbook cum diary on regulatory information
2. Drug regulatory officials giving the nod for sale of Unapproved drug formulations in India
3. Tumor Suppressor p53s Contradictory Regulatory System
4. Human Complexity Can Be Attributed To Regulatory Sequence
5. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
6. Medtronic’s Insulin Pump Receives Regulatory Approva
7. Regulatory T-cells – Protector or Cause of Diseases
8. GMC Wrestles For Regulatory Powers
9. Regulatory Mechanism for Tumor Suppressor Protein Identified
10. Structure of Iron Regulatory Protein-RNA Complex Solved
11. Ramadoss Vows to Set Up Food Regulatory Body in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... Memorial Healthcare System Graduate Medical ... (ACGME) that it has received accreditation for its residency program on Physical Medicine ... that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members ... celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care ... Cumming), offers a 70% tax credit to individuals and corporations which donate directly to ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White ... repaying their loans, more information about their loan terms and accounts, and more ... loan debt, including federal and private loans, has reached $1.3 trillion, with 43 ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology: